Open-house rebate agreements for Etanercept
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Etanercept, ATC L04AB01
Opportunity Score
Why this score?
Opportunity
52 / 100
Complexity
58 / 100
Risk factors
For paper submissions, the notice requires duplicate originals and a prior fax/scan/email/portal transmission only pres...
Participation is limited to pharmaceutical companies and requires a signed reliability self-declaration.
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive rebate agreements for the medicinal product Etanercept, ATC L04AB01.
- Open-house model with identical, pre-set contract terms for all eligible pharmaceutical companies.
Show full summary
Open-house supply arrangement for pharmaceutical products: non-exclusive rebate agreements for Etanercept (ATC L04AB01) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated suitability requirement. This is explicitly described as a non-competitive open-house model with no selection decision and no negotiated terms. Contracting is possible throughout the term, with the latest contract conclusion date on 2026-09-05. Submission can be made electronically with a qualified electronic signature or in paper form; documents not in German must be submitted with a German translation.
Risks
For paper submissions, the notice requires duplicate originals and a prior fax/scan/email/portal transmission only pres...
Participation is limited to pharmaceutical companies and requires a signed reliability self-declaration.
Submission deadline in 8 days
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- Submission of a completed and signed self-declaration on reliability (Eigenerklärung zur Zuverlässigkeit).
- Submission of the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open-house rebate agreements for Etanercept
Open-house supply lot for non-exclusive rebate agreements concerning the active substance Etanercept (ATC L04AB01). The notice states that all interested pharmaceutical companies meeting the suitability requirement may join on identical, non-individually negotiable terms. Place of performance is Germany, specifically DE212 (Bavaria/Munich region in the notice metadata).
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Etanercept, ATC L04AB01
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 16 Sep 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 557440-2024
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
52 / 100
Complexity
58 / 100
Risk factors
For paper submissions, the notice requires duplicate originals and a prior fax/scan/email/portal transmission only pres...
Participation is limited to pharmaceutical companies and requires a signed reliability self-declaration.
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications